Table 2.
Baseline demographics by disease sub-group and alemtuzumab dose received
| AAV (high dose) N = 6 | AAV (low dose) N = 6 | BD (high dose) N = 4 |
BD (low dose) N = 7 |
||
|---|---|---|---|---|---|
| Age | 41 (41–46) | 42 (22–49) | 39 (28–41) | 29 (25–44) | |
| Median disease duration in months | 52 (38–95) | 108 (52–109) | 61 (50–71) | 68 (16–108) | |
| BVAS/WG score at entry (median; IQR) | 4.5 (4.0–5.0) | 5.0 (4.0–6.0) | BDCAF at entry (median, IQR) | 10.5 (9.75–11.2) | 8 (8–8) |
| BVAS/WG score 6 M | 1 (0–1) | 1 (0–3) | BDCAF score at 6 M | 8 (6.5–9.25) | 5 (0–8) |
| BVAS/WG score at 12 M | 0 (0–2) | 0 (0–0) | BDCAF score at 12 M | 0 (0–3.5) | 4.5 (0–9) |